AllRock Bio just locked in a $50 million Series A, and it feels less like a funding round and more like the opening drop of a marathon set that makes the room shift. Founded in 2023 out of JucaBio, this Natick-based biotech is coming out of stealth swinging, led by Catherine Pearce, DHSc, MBA, and Justin R Thompson. Their focus? cardiopulmonary and fibrotic diseases where survival rates read more like a gut punch than a prognosis. This isn’t a vanity play, it’s life-or-death science.
The round, co-led by Versant Ventures and Westlake BioPartners, fuels ROC-101 into Phase 2 clinical development. ROC-101 isn’t just another therapy candidate. It’s a first-in-class, oral pan-ROCK inhibitor that targets both ROCK1 and ROCK2 enzymes, going after inflammatory, proliferative, and fibrotic remodeling in pulmonary arterial hypertension and ILD-PH. Current therapies only loosen the arteries. ROC-101 aims to rewrite the pathophysiology itself, anti-proliferative, anti-inflammatory, and anti-fibrotic in one clean strike.
The story runs deep. Catherine Pearce first saw ROC-101 a decade ago under Kadmon Holdings. After Sanofi scooped Kadmon Holdings for $1.9 billion, and AstraZeneca acquired CinCor Pharma, the company Pearce and Thompson helped steer, for up to $1.8 billion, the playbook was clear. License ROC-101, bring in a team with scars and wins, and build it right. Now, that molecule has a new lease on life, with Phase 1 data showing safety, tolerability, and exposures aligning perfectly with predictive models. No hype, just validation.
The stakes are massive. PAH impacts roughly 40,000 people in the U.S., and five-year survival rates are stuck at 57 percent for PAH, 38 percent for ILD-PH. The global market sits near $9 billion and could climb to $13 billion by the mid-2030s. That’s growth powered not by marketing spin but by desperation for therapies that actually move survival curves.
ROC-101 will head into the ROCSTAR Phase 2a trial in late 2025, paired with standard-of-care therapy. Backing this are veterans: Bill Marshall as CMO, M. Kathryn Steiner driving clinical development, and Jack Greene anchoring manufacturing. On the board, David Allison from Westlake and Alicia Levey from Versant. Surrounding them, a scientific advisory board stacked with global leaders like Mardi Gomberg, Marius Hoeper, Steven Nathan, Aaron Waxman, Oksana Shlobin, and Vallerie McLaughlin.
AllRock Bio isn’t betting on flash. They’re betting on execution, on carrying ROC-101 through Phase 2 and beyond, partnership or not. Catherine Pearce and Justin R Thompson have proven they can build companies that end in billion-dollar exits. Now they’re chasing something heavier: changing the survival math for patients who have been left behind. Versant Ventures and Westlake BioPartners see it. The rest of the industry should take note, the reverberations of this round won’t fade quietly.
